Burkina Faso

Accomplishments

Burkina Faso has stopped mass drug administration (MDA) for lymphatic filariasis in 89% of endemic districts in the country following interruption of transmission of the causative parasite in 62 districts as of FY20 (October 2019 – September 2020). Prevalence of infection has been reduced significantly in the remaining eight districts due to ongoing MDA.

All trachoma endemic health districts have reached the elimination threshold of trachomatous inflammation—follicular (TF) of less than 5% among children ages 1-9 and have stopped MDA as of FY18 (October 2017 – September 2018).

Burkina Faso has implemented MDA against SCH/STH since 2004. Prevalence of infection has been reduced and in 2021 the country ceased treatment for STH in the whole country following recommendations from WHO. As a result of eight to nine rounds of high coverage MDA, Burkina Faso will conduct a schistosomiasis (and soil-transmitted helminthiasis) impact assessment in 15 districts in 2022.

Standard Disease-Specific Indicators as of FY20

FY20 is October 2019 through September 2020

LYMPHATIC FILARIASIS

of ever-endemic districts have stopped MDA as of FY20

(i.e. have passed stop MDA survey, TAS1 (First Transmission Assessment Survey))

of ever-endemic districts in post-surveillance phase as of FY20

(i.e. have passed last surveillance survey, TAS3 (third Transmission Assessment Survey))

of persons no longer at risk as of FY20 among those who were ever at risk

TRACHOMA

of ever-endemic districts have stopped MDA as of FY20

(i.e. have passed stop MDA survey, TIS (Trachoma Impact Survey))

syringe

percentage of ever-endemic districts in post-surveillance phase as of FY20

(i.e. have passed surveillance survey, TSS (Trachoma Surveillance Survey))*

*Burkina Faso has conducted TSS in 36 districts; however, data are only available for 35. 5 additional TSS are planned by the end of FY21. The remaining 7 HDs are insecure